The valuations of Ajanta Pharma, a pharma major is increasing. Its reserves on annualized basis are constantly on the rise and so is the case with sales and net profit/margins on quarterly basis. At the current EPS, it is somewhat over priced and should be bought for med term ; especially with SIP Mode.
It is suffering from higher price to earning at 34 when compared with industry PE of around 31. Otherwise, almost with debt free status, a good dividend pay master with CRR and DPR ratio o 85 : 15, it is a clear buy on each dip. Even its profit generating efficiency level is 36% as on Mar 15.
Kindly buy on each dip for decent return provided it is held with conviction.